The expression of the nuclear matrix proteins NuMA, topoisomerase II-α, and -β in bone and osseous cell culture: Regulation by parathyroid hormone

H. A. Feister, J. E. Onyia, R. R. Miles, X. Yang, R. Galvin, J. M. Hock, Joseph Bidwell

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Bone cells undergo changes in cell structure during phenotypic development. Parathyroid hormone (PTH) induces a change in osteoblast shape, a determinant of collagen expression. We hypothesize that alterations in bone cell shape reflect and direct gene expression as governed, in part, by nuclear organization. In this study, we determined whether the expression of nuclear matrix proteins that mediate nuclear architecture, NuMA, topoisomerase II (topo II)-α, and -β, were altered during osteoblast development and response to PTH in vivo. NuMA forms an interphase nuclear scaffold in some cells, the absence of which may accommodate alterations in nuclear organization necessary for specific functions. Topo II enzymes are expressed in bone cells; the α-isoform is specific to proliferating cells. We used immunohistochemistry and flow cytometry to determine whether NuMA is expressed in the primary spongiosa of the rat metaphyseal femur and whether expression of NuMA, topo II-α, and II-β changes during osteoblast development or with PTH treatment. NuMA and topo II-β were expressed in marrow cells, osteoblasts, osteocytes, and chondrocytes. These proteins were not detected in osteoclasts in vivo, but were observed in cultured cells. Bone marrow cells expressed topo II-α. All three proteins were expressed in cultures of rat osteoblast-like UMR-106 cells. PTH treatment downregulated the number of topo II-α-immunopositive cells, correlated with a decrease in S-phase cells, in both bone tissue and cell culture. We conclude that, in vivo, nuclear matrix composition is altered during bone cell development and that anabolic doses of PTH attenuate the proliferative capacity of osteogenic cells, in part, by targeting topo II-α expression. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)227-234
Number of pages8
JournalBone
Volume26
Issue number3
DOIs
StatePublished - Mar 2000

Fingerprint

Nuclear Matrix-Associated Proteins
Type II DNA Topoisomerase
Parathyroid Hormone
Cell Culture Techniques
Bone and Bones
Osteoblasts
Nuclear Matrix
Osteocytes
Cell Shape
Bone Development
Interphase
Osteoclasts
Chondrocytes
S Phase
Bone Marrow Cells
Femur
Cultured Cells
Flow Cytometry
Protein Isoforms
Proteins

Keywords

  • Anabolic
  • Bone
  • Nuclear matrix
  • NuMA
  • Parathyroid hormone
  • Topoisomerase II

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

The expression of the nuclear matrix proteins NuMA, topoisomerase II-α, and -β in bone and osseous cell culture : Regulation by parathyroid hormone. / Feister, H. A.; Onyia, J. E.; Miles, R. R.; Yang, X.; Galvin, R.; Hock, J. M.; Bidwell, Joseph.

In: Bone, Vol. 26, No. 3, 03.2000, p. 227-234.

Research output: Contribution to journalArticle

Feister, H. A. ; Onyia, J. E. ; Miles, R. R. ; Yang, X. ; Galvin, R. ; Hock, J. M. ; Bidwell, Joseph. / The expression of the nuclear matrix proteins NuMA, topoisomerase II-α, and -β in bone and osseous cell culture : Regulation by parathyroid hormone. In: Bone. 2000 ; Vol. 26, No. 3. pp. 227-234.
@article{8612a893337e44be8ff18393665105ab,
title = "The expression of the nuclear matrix proteins NuMA, topoisomerase II-α, and -β in bone and osseous cell culture: Regulation by parathyroid hormone",
abstract = "Bone cells undergo changes in cell structure during phenotypic development. Parathyroid hormone (PTH) induces a change in osteoblast shape, a determinant of collagen expression. We hypothesize that alterations in bone cell shape reflect and direct gene expression as governed, in part, by nuclear organization. In this study, we determined whether the expression of nuclear matrix proteins that mediate nuclear architecture, NuMA, topoisomerase II (topo II)-α, and -β, were altered during osteoblast development and response to PTH in vivo. NuMA forms an interphase nuclear scaffold in some cells, the absence of which may accommodate alterations in nuclear organization necessary for specific functions. Topo II enzymes are expressed in bone cells; the α-isoform is specific to proliferating cells. We used immunohistochemistry and flow cytometry to determine whether NuMA is expressed in the primary spongiosa of the rat metaphyseal femur and whether expression of NuMA, topo II-α, and II-β changes during osteoblast development or with PTH treatment. NuMA and topo II-β were expressed in marrow cells, osteoblasts, osteocytes, and chondrocytes. These proteins were not detected in osteoclasts in vivo, but were observed in cultured cells. Bone marrow cells expressed topo II-α. All three proteins were expressed in cultures of rat osteoblast-like UMR-106 cells. PTH treatment downregulated the number of topo II-α-immunopositive cells, correlated with a decrease in S-phase cells, in both bone tissue and cell culture. We conclude that, in vivo, nuclear matrix composition is altered during bone cell development and that anabolic doses of PTH attenuate the proliferative capacity of osteogenic cells, in part, by targeting topo II-α expression. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Anabolic, Bone, Nuclear matrix, NuMA, Parathyroid hormone, Topoisomerase II",
author = "Feister, {H. A.} and Onyia, {J. E.} and Miles, {R. R.} and X. Yang and R. Galvin and Hock, {J. M.} and Joseph Bidwell",
year = "2000",
month = "3",
doi = "10.1016/S8756-3282(99)00269-0",
language = "English",
volume = "26",
pages = "227--234",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The expression of the nuclear matrix proteins NuMA, topoisomerase II-α, and -β in bone and osseous cell culture

T2 - Regulation by parathyroid hormone

AU - Feister, H. A.

AU - Onyia, J. E.

AU - Miles, R. R.

AU - Yang, X.

AU - Galvin, R.

AU - Hock, J. M.

AU - Bidwell, Joseph

PY - 2000/3

Y1 - 2000/3

N2 - Bone cells undergo changes in cell structure during phenotypic development. Parathyroid hormone (PTH) induces a change in osteoblast shape, a determinant of collagen expression. We hypothesize that alterations in bone cell shape reflect and direct gene expression as governed, in part, by nuclear organization. In this study, we determined whether the expression of nuclear matrix proteins that mediate nuclear architecture, NuMA, topoisomerase II (topo II)-α, and -β, were altered during osteoblast development and response to PTH in vivo. NuMA forms an interphase nuclear scaffold in some cells, the absence of which may accommodate alterations in nuclear organization necessary for specific functions. Topo II enzymes are expressed in bone cells; the α-isoform is specific to proliferating cells. We used immunohistochemistry and flow cytometry to determine whether NuMA is expressed in the primary spongiosa of the rat metaphyseal femur and whether expression of NuMA, topo II-α, and II-β changes during osteoblast development or with PTH treatment. NuMA and topo II-β were expressed in marrow cells, osteoblasts, osteocytes, and chondrocytes. These proteins were not detected in osteoclasts in vivo, but were observed in cultured cells. Bone marrow cells expressed topo II-α. All three proteins were expressed in cultures of rat osteoblast-like UMR-106 cells. PTH treatment downregulated the number of topo II-α-immunopositive cells, correlated with a decrease in S-phase cells, in both bone tissue and cell culture. We conclude that, in vivo, nuclear matrix composition is altered during bone cell development and that anabolic doses of PTH attenuate the proliferative capacity of osteogenic cells, in part, by targeting topo II-α expression. Copyright (C) 2000 Elsevier Science Inc.

AB - Bone cells undergo changes in cell structure during phenotypic development. Parathyroid hormone (PTH) induces a change in osteoblast shape, a determinant of collagen expression. We hypothesize that alterations in bone cell shape reflect and direct gene expression as governed, in part, by nuclear organization. In this study, we determined whether the expression of nuclear matrix proteins that mediate nuclear architecture, NuMA, topoisomerase II (topo II)-α, and -β, were altered during osteoblast development and response to PTH in vivo. NuMA forms an interphase nuclear scaffold in some cells, the absence of which may accommodate alterations in nuclear organization necessary for specific functions. Topo II enzymes are expressed in bone cells; the α-isoform is specific to proliferating cells. We used immunohistochemistry and flow cytometry to determine whether NuMA is expressed in the primary spongiosa of the rat metaphyseal femur and whether expression of NuMA, topo II-α, and II-β changes during osteoblast development or with PTH treatment. NuMA and topo II-β were expressed in marrow cells, osteoblasts, osteocytes, and chondrocytes. These proteins were not detected in osteoclasts in vivo, but were observed in cultured cells. Bone marrow cells expressed topo II-α. All three proteins were expressed in cultures of rat osteoblast-like UMR-106 cells. PTH treatment downregulated the number of topo II-α-immunopositive cells, correlated with a decrease in S-phase cells, in both bone tissue and cell culture. We conclude that, in vivo, nuclear matrix composition is altered during bone cell development and that anabolic doses of PTH attenuate the proliferative capacity of osteogenic cells, in part, by targeting topo II-α expression. Copyright (C) 2000 Elsevier Science Inc.

KW - Anabolic

KW - Bone

KW - Nuclear matrix

KW - NuMA

KW - Parathyroid hormone

KW - Topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=0033970074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033970074&partnerID=8YFLogxK

U2 - 10.1016/S8756-3282(99)00269-0

DO - 10.1016/S8756-3282(99)00269-0

M3 - Article

C2 - 10709994

AN - SCOPUS:0033970074

VL - 26

SP - 227

EP - 234

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -